W. Kugler

Some Numerical Studies of the Evolution of Generalized Parton Distributions. (2008)

M. Diehl, DESY Forschung Hochenergiephysik, W. Kugler

Journal article

Next-to-leading order corrections in exclusive meson production (2007)

Diehl, M., Kugler, W.

We analyze in detail the size of next-to-leading order corrections to hard exclusive meson production within the collinear factorization approach. Corrections to the cross section are found to be...

Exclusive Meson Production at NLO (2007)

Diehl, M., Kugler, W.

We report on numerical studies of the NLO corrections to exclusive meson electroproduction, both in collider and fixed-target kinematics. Corrections are found to be huge at small xB and sizeable at...

Next-to-leading Order Corrections in Exclusive Meson Production. (2007)

M. Diehl, DESY Forschung Hochenergiephysik, W. Kugler

Journal article

Some Numerical Studies of the Evolution of Generalized Parton Distributions. (2007)

M. Diehl, DESY Forschung Hochenergiephysik, W. Kugler

Internal report | Preprint

Next-to-leading Order Corrections in Exclusive Meson Production. (2007)

M. Diehl, DESY Forschung Hochenergiephysik, W. Kugler

Internal report | Preprint

Exclusive Meson Production at NLO. 2007-04-16 - 2007-04-20 (2007)

M. Diehl, DESY Forschung Hochenergiephysik, W. Kugler, G. Grindhammer, K. Sachs (ed.)

Contribution to a conf. proceeding (book/online)

Exclusive Meson Production at NLO. (2007)

M. Diehl, DESY Forschung Hochenergiephysik, W. Kugler

Internal report | Preprint

Increased transfer of antibodiesto the CNS using BBB opening with 1-O-pentylglycerol and 2-O-hexyldiglycerol: Visualization of drug transfer using in vivo optical imaging (2006)

Erdlenbruch, B., Preusse, A., Huelper, P., Kugler, W., Eibl, H., Lakomek, M.

Exclusive channels in semi-inclusive production of pions and kaons (2005)

Diehl, M., Kugler, W., Schaefer, A., Weiss, C.

We investigate the role of exclusive channels in semi-inclusive electroproduction of pions and kaons. Using the QCD factorization theorem for hard exclusive processes we evaluate the cross sections...

Blood-brain barrier opening with alkylglycerols: Biodistribution of 1-O-pentylglycerol after intravenous and intracarotid administration in rats (2005)

Erdlenbruch, B., Kugler, W., Schinkhof, C., Neurath, H., Eibl, H., Lakomek, M.

Downregulation of Apaf-1 and caspase-3 by RNA interference in human glioma cells: Consequences for erucylphosphocholine-induced apoptosis (2005)

Kugler, W., Buchholz, F., Kohler, F., Eibl, H., Lakomek, M., Erdlenbruch, B.

Downregulation of Apaf-1 and caspase-3 by RNA interference in human glioma cells: Consequences for erucylphosphocholine-induced apoptosis (2005)

Kugler, W., Buchholz, F., Koehler, F., Eibl, H., Lakomek, M., Erdlenbruch, B.

MAP kinase pathways involved in glioblastoma response to erucylphosphocholine (2004)

Kugler, W., Erdlenbruch, B., Otten, K., Jendrossek, V., Eibl, H., Lakomek, M.

Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain (2003)

Erdlenbruch, B., Schinkhof, C., Kugler, W., Heinemann, D., Herms, J., Eibl, H., ...

Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries (2003)

Erdlenbruch, B., Alipour, M., Fricker, G., Miller, D. S., Kugler, W., Eibl, H., ...

Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro (2002)

Jendrossek, V., Hammersen, K., Erdlenbruch, B., Kugler, W., Krugener, R., Eibl, H., ...

Erucylphosphocholine (ErPC) is a promising candidate for the treatment of human brain tumors. The aim of the present study was to investigate whether structural modifications of ErPC would improve...

Erucylphosphocholine-induced apoptosis in glioma cells: involvement of death receptor signalling and caspase activation (2002)

Kugler, W., Erdlenbruch, B., Junemann, A., Heinemann, D., Eibl, H., Lakomek, M.

Erucylphosphocholine (ErPC) is a promising anti-neoplastic drug for the treatment of malignant brain tumours. It exerts strong anti-cancer activity in vivo and in vitro and induces apoptosis even in...

Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats (2002)

Erdlenbruch, B., Jendrossek, V., Kugler, W., Eibl, H., Lakomek, M.

Background: Erucylphosphocholine (ErPC) has been shown to exert strong antineoplastic effects against various brain tumor cell lines in vitro. Since ErPC only enters the brain after long- term...

Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: Involvement of caspase activation and mitochondrial alterations (2001)

Jendrossek, V., Kugler, W., Erdlenbruch, B., Eibl, H., Lang, F., Lakomek, M.

Intrinsic chemoresistance constitutes a major problem in the therapy of malignant gliomas. In vitro experiments with four astrocytoma/glioblastoma (AC/GBM) cell lines revealed that the...

Erucylphosphocholine, a novel antineoplastic either lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. (1999)

Jendrossek, V., Erdlenbruch, B., Hunold, A., Kugler, W., Eibl, H., Lakomek, M.

Determination of mRNA fate by different RNA polymerase II promoters.

Enssle, J, Kugler, W, Hentze, M W, Kulozik, A E

Translational stop mutations of the human beta-globin gene cause a reduction of cytoplasmic mRNA accumulation in thalassemia patients and in transfection models. The exact mechanism underlying this...

Nuclear degradation of nonsense mutated beta-globin mRNA: a post-transcriptional mechanism to protect heterozygotes from severe clinical manifestations of beta-thalassemia?

Kugler, W, Enssle, J, Hentze, M W, Kulozik, A E

Nonsense mutations of the beta-globin gene are a common cause of beta-thalassemia. It is a hallmark of these mutations not only to cause a lack of protein synthesis but also a reduction of mRNA...

Liver cell specific gene transcription in vitro: the promoter elements HP1 and TATA box are necessary and sufficient to generate a liver-specific promoter.

Ryffel, G U, Kugler, W, Wagner, U, Kaling, M

The hepatocyte-specific promoter element HP1, which is present in several genes specifically expressed in the liver, is active in an in vitro transcription system. The liver-specificity is retained...

BAP, a rat liver protein that activates transcription through a promoter element with similarity to the USF/MLTF binding site.

Kugler, W, Kaling, M, Ross, K, Wagner, U, Ryffel, G U

The vitellogenin genes of Xenopus are liver-specifically expressed. An in vitro transcription system derived from rat liver nuclei allowed us to define the cis-element BABS (B-activator binding site)...

Tissue-specificity of liver gene expression: a common liver-specific promoter element.

Kugler, W, Wagner, U, Ryffel, G U

Several liver specific genes contain a sequence similar to the hepatocyte-specific promoter element (HP1) identified in the Xenopus albumin gene. By competition experiments in gel retardation assays...

Liver-specific gene expression: A-activator-binding site, a promoter module present in vitellogenin and acute-phase genes.

Kaling, M, Kugler, W, Ross, K, Zoidl, C, Ryffel, G U

The A2 vitellogenin gene of Xenopus laevis, which is expressed liver specifically, contains an A-activator-binding site (AABS) that mediates high in vitro transcriptional activity in rat liver...

Determination of mRNA fate by different RNA polymerase II promoters.

Enssle, J, Kugler, W, Hentze, M W, Kulozik, A E

Translational stop mutations of the human beta-globin gene cause a reduction of cytoplasmic mRNA accumulation in thalassemia patients and in transfection models. The exact mechanism underlying this...

Nuclear degradation of nonsense mutated beta-globin mRNA: a post-transcriptional mechanism to protect heterozygotes from severe clinical manifestations of beta-thalassemia?

Kugler, W, Enssle, J, Hentze, M W, Kulozik, A E

Nonsense mutations of the beta-globin gene are a common cause of beta-thalassemia. It is a hallmark of these mutations not only to cause a lack of protein synthesis but also a reduction of mRNA...

Liver cell specific gene transcription in vitro: the promoter elements HP1 and TATA box are necessary and sufficient to generate a liver-specific promoter.

Ryffel, G U, Kugler, W, Wagner, U, Kaling, M

The hepatocyte-specific promoter element HP1, which is present in several genes specifically expressed in the liver, is active in an in vitro transcription system. The liver-specificity is retained...

BAP, a rat liver protein that activates transcription through a promoter element with similarity to the USF/MLTF binding site.

Kugler, W, Kaling, M, Ross, K, Wagner, U, Ryffel, G U

The vitellogenin genes of Xenopus are liver-specifically expressed. An in vitro transcription system derived from rat liver nuclei allowed us to define the cis-element BABS (B-activator binding site)...

Tissue-specificity of liver gene expression: a common liver-specific promoter element.

Kugler, W, Wagner, U, Ryffel, G U

Several liver specific genes contain a sequence similar to the hepatocyte-specific promoter element (HP1) identified in the Xenopus albumin gene. By competition experiments in gel retardation assays...

Liver-specific gene expression: A-activator-binding site, a promoter module present in vitellogenin and acute-phase genes.

Kaling, M, Kugler, W, Ross, K, Zoidl, C, Ryffel, G U

The A2 vitellogenin gene of Xenopus laevis, which is expressed liver specifically, contains an A-activator-binding site (AABS) that mediates high in vitro transcriptional activity in rat liver...